Biodesix, Inc. (BDSX)
Company Description
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States.
The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions.
It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection.
In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics.
The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
| Country | United States |
| IPO Date | Oct 28, 2020 |
| Industry | Diagnostics & Research |
| Sector | Health Care |
| Employees | 200 |
Contact Details
Address: 2970 Wilderness Place Boulder, CO 80301 United States | |
| Phone | 303 417 0500 |
| Website | biodesix.com |
Stock Details
| Ticker Symbol | BDSX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $18.00 |
| CIK Code | 0001439725 |
Key Executives
| Name | Position |
|---|---|
| Scott Hutton | President, Chief Executive Officer and Director |
| Robin Harper Cowie | Chief Financial Officer, Secretary and Treasurer |
| Kieran O'Kane | Chief Commercial Officer |
| Dr. Heinrich Röder | Founder and Chief Technology Officer |
| Robert E. Cawthorn | Founder and Director Emeritus |
| Ryan H. Siurek | Chief Accounting Officer |
| Jeffrey A. Bojar | Vice President of Legal and Regulatory Affairs |
| Matt Stauffer | Vice President of Sales |
| Dr. Paul J. Beresford | Chief Business Officer |
| Dr. Gary Anthony Pestano Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jan 10, 2022 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 7, 2022 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals |
| Jan 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jan 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jan 4, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jan 4, 2022 | SC 13D/A | General statement of acquisition of beneficial ownership |
| Jan 4, 2022 | 8-K | Current report |
| Dec 22, 2021 | 4 | Statement of changes in beneficial ownership of securities |
| Dec 22, 2021 | 424B5 | Prospectus [Rule 424(b)(5)] |
| View All SEC Filings | ||